Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Outlook Therapeutics Inc (OTLK)

$1.71 +0.10 (6.21%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	239.48M
Revenue (ttm)	1.41M
Net Income (ttm)	-62.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,426.95%
Debt to Equity Ratio	-0.55

Volume	11,491,900
Avg Vol	22,122,934
Day's Range	N/A - N/A
Shares Out	140.05M
Stochastic %K	77%
Beta	0.94
Analysts	Sell
Price Target	$5.50

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

DidYouReadThis Jun. 29 at 7:36 AM

What might close 2026 higher per share? $SNAP vs $OTLK whose PDUFA is 7/29/26?

0 · Reply

DidYouReadThis Jun. 29 at 7:16 AM

$KDP #BABY! & $OTLK

0 · Reply

Noetic83 Jun. 29 at 6:55 AM

$OTLK

0 · Reply

lockii Jun. 29 at 6:04 AM

had terrbile weekend pls save me $OTLK

1 · Reply

DidYouReadThis Jun. 29 at 6:00 AM

$WKHS 7/29/26 market close, what do you think will have a higher price per share? $OTLK has a #PDUFA 7/29/26

0 · Reply

mmc100 Jun. 29 at 5:19 AM

$OTLK ...all looking good. Hopefully $3+ this week. Feeling very.....

0 · Reply

DidYouReadThis Jun. 29 at 3:57 AM

What’s more likely to happen first, $DIS ? $OTLK Good luck Outlook Therapeutics on #PDUFA 7/29/26!!!

2 · Reply

DidYouReadThis Jun. 29 at 3:44 AM

What’s more likely to happen first in a single day? $SLS Good luck $OTLK 7/29/26 #PDUFA! #POTENTIAL #BLOCKBUSTER #VOLUME #incoming?

0 · Reply

Wisvest Jun. 29 at 3:20 AM

$OTLK

1 · Reply

DidYouReadThis Jun. 29 at 3:03 AM

In your opinion, what’s more likely: $RDDT PE below 20 $OTLK PE above 40 sometime after 7/29/26 #PDUFA? $META

0 · Reply

Outlook Therapeutics resubmits ONS-5010 biologics license application to FDA

Jun 16, 2026, 8:02 AM EDT - 12 days ago

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

2026-06-01T14:01:40.000Z - 27 days ago

Outlook Therapeutics resubmits biologics license application to FDA

Jun 1, 2026, 8:46 AM EDT - 27 days ago

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Jun 1, 2026, 8:00 AM EDT - 27 days ago

Outlook Therapeutics Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 27 days ago

Outlook Therapeutics Proxy statement: Proxy filing

2026-05-28T20:10:47.000Z - 4 weeks ago

Outlook Therapeutics announces pricing of $5M registered direct offering

2026-05-28T20:08:09.000Z - 4 weeks ago

Outlook to sell 8.54M shares at 58.55c in registered direct offering

May 28, 2026, 4:00 PM EDT - 4 weeks ago

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2026-05-26T11:53:46.000Z - 4 weeks ago

Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava

May 26, 2026, 7:00 AM EDT - 4 weeks ago

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

May 22, 2026, 8:00 AM EDT - 5 weeks ago

Outlook Therapeutics Proxy statement: Proxy filing

2026-05-18T10:10:08.000Z - 5 weeks ago

Outlook Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-15T20:18:39.000Z - 6 weeks ago

Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)

May 15, 2026, 4:05 PM EDT - 6 weeks ago

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

May 15, 2026, 7:00 AM EDT - 6 weeks ago

Outlook Therapeutics Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 6 weeks ago

Outlook Therapeutics Earnings release: Q2 2026

Apr 23, 2026, 4:05 PM EDT - 2 months ago

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

2026-04-22T14:29:53.000Z - 2 months ago

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2026-04-21T15:24:19.000Z - 2 months ago

Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA

Apr 21, 2026, 9:05 AM EDT - 2 months ago

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

2026-04-07T13:19:03.000Z - 2 months ago

Outlook Therapeutics submits formal dispute resolution request to FDA

Apr 7, 2026, 8:50 AM EDT - 2 months ago

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

Mar 25, 2026, 4:05 PM EDT - 3 months ago

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Mar 24, 2026, 7:00 AM EDT - 3 months ago

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

2026-03-23T21:35:25.000Z - 3 months ago

Outlook Therapeutics announces common stock, warrant offering, no amount given

Mar 23, 2026, 5:30 PM EDT - 3 months ago

Outlook Therapeutics Announces Proposed Public Offering

2026-03-16T12:41:35.000Z - 3 months ago

Outlook Therapeutics announces $18.4M non-convertible note financing

Mar 16, 2026, 8:05 AM EDT - 3 months ago

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

2026-03-11T12:55:42.000Z - 3 months ago

Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant

2026-03-05T21:55:20.000Z - 4 months ago

Outlook Therapeutics provides update following FDA meeting on ONS-5010

Mar 5, 2026, 4:15 PM EST - 4 months ago

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

2026-02-19T14:16:05.000Z - 4 months ago

Outlook enters distribution agreement for sale of Lytenava in Switzerland

Feb 19, 2026, 9:00 AM EST - 4 months ago

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

2026-02-17T13:16:40.000Z - 4 months ago

Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

Feb 17, 2026, 8:05 AM EST - 4 months ago

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 17, 2026, 8:00 AM EST - 4 months ago

Outlook Therapeutics Quarterly report: Q1 2026

Feb 17, 2026, 8:00 AM EST - 4 months ago

Outlook Therapeutics Earnings release: Q1 2026

2026-02-11T13:50:19.000Z - 4 months ago

Outlook Therapeutics sumbits Type A meeting request to FDA

Feb 11, 2026, 8:45 AM EST - 4 months ago

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Jan 26, 2026, 7:00 AM EST - 5 months ago

Outlook Therapeutics Proxy statement: Proxy Filing

Jan 26, 2026, 7:00 AM EST - 5 months ago

Outlook Therapeutics Proxy statement: Proxy Filing

Jan 6, 2026, 8:35 AM EST - 6 months ago

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Dec 31, 2025, 4:23 PM EST - 6 months ago

US FDA declines to approve Outlook Therapeutics' eye disease drug

Dec 31, 2025, 4:15 PM EST - 6 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Dec 26, 2025, 5:00 PM EST - 6 months ago

Outlook Therapeutics Announces New Employment Inducement Grants

Dec 19, 2025, 8:30 AM EST - 6 months ago

Outlook Therapeutics Annual report: Q4 2025

Dec 19, 2025, 8:30 AM EST - 6 months ago

Outlook Therapeutics Earnings release: Q4 2025

Dec 19, 2025, 8:05 AM EST - 6 months ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dec 2, 2025, 10:00 AM EST - 7 months ago

Outlook Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:05 AM EST - 7 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 8 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 3, 2025, 8:35 AM EST - 8 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Sep 29, 2025, 8:45 AM EDT - 9 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 3, 2025, 8:35 AM EDT - 10 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 2, 2025, 8:35 AM EDT - 10 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Aug 28, 2025, 11:51 AM EDT - 10 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 8:30 AM EDT - 10 months ago

Outlook Therapeutics Transcript: Status Update

Aug 28, 2025, 8:30 AM EDT - 10 months ago

Outlook Therapeutics Press release: Status Update

Aug 28, 2025, 6:39 AM EDT - 10 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 14, 2025, 8:05 AM EDT - 11 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 12:00 AM EDT - 11 months ago

Outlook Therapeutics Quarterly report: Q3 2025

Aug 14, 2025, 12:00 AM EDT - 11 months ago

Outlook Therapeutics Earnings release: Q3 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 1 year ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Outlook Therapeutics Slides: Corporate Presentation

Jun 25, 2025, 12:00 PM EDT - 1 year ago

Outlook Therapeutics Transcript: Status Update

Jun 18, 2025, 9:05 AM EDT - 1 year ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 1 year ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 1 year ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 1 year ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Earnings release: Q2 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

Outlook Therapeutics Quarterly report: Q2 2025

Apr 8, 2025, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Outlook Therapeutics Registration statement: Registration Filing

Feb 28, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Registration statement: Registration Filing

Feb 19, 2025, 9:00 AM EST - 1 year ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Quarterly report: Q1 2025

Feb 14, 2025, 8:00 AM EST - 1 year ago

Outlook Therapeutics Earnings release: Q1 2025

Feb 10, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 3, 2025, 7:00 PM EST - 1 year ago

Outlook Therapeutics Transcript: Study Update

Jan 31, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 7:00 AM EST - 1 year ago

Outlook Therapeutics Proxy statement: Proxy Filing

Jan 23, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 6:00 AM EST - 1 year ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

DidYouReadThis Jun. 29 at 7:36 AM

What might close 2026 higher per share? $SNAP vs $OTLK whose PDUFA is 7/29/26?

0 · Reply

DidYouReadThis Jun. 29 at 7:16 AM

$KDP #BABY! & $OTLK

0 · Reply

Noetic83 Jun. 29 at 6:55 AM

$OTLK

0 · Reply

lockii Jun. 29 at 6:04 AM

had terrbile weekend pls save me $OTLK

1 · Reply

DidYouReadThis Jun. 29 at 6:00 AM

$WKHS 7/29/26 market close, what do you think will have a higher price per share? $OTLK has a #PDUFA 7/29/26

0 · Reply

mmc100 Jun. 29 at 5:19 AM

$OTLK ...all looking good. Hopefully $3+ this week. Feeling very.....

0 · Reply

DidYouReadThis Jun. 29 at 3:57 AM

What’s more likely to happen first, $DIS ? $OTLK Good luck Outlook Therapeutics on #PDUFA 7/29/26!!!

2 · Reply

DidYouReadThis Jun. 29 at 3:44 AM

What’s more likely to happen first in a single day? $SLS Good luck $OTLK 7/29/26 #PDUFA! #POTENTIAL #BLOCKBUSTER #VOLUME #incoming?

0 · Reply

Wisvest Jun. 29 at 3:20 AM

$OTLK

1 · Reply

DidYouReadThis Jun. 29 at 3:03 AM

In your opinion, what’s more likely: $RDDT PE below 20 $OTLK PE above 40 sometime after 7/29/26 #PDUFA? $META

0 · Reply

DidYouReadThis Jun. 29 at 2:50 AM

If $HOOD #earnings are 7/29/26, and if potential #blockbuster $OTLK has a 7/29/26 #PDUFA, which do you expect to have a greater potential increase in #July?

0 · Reply

Sharelion Jun. 29 at 2:13 AM

$OTLK Today we will have PR of above 1$

3 · Reply

Sharelion Jun. 29 at 2:05 AM

$OTLK Today 2.10

0 · Reply

AnalystLLM Jun. 29 at 1:51 AM

$OTLK (1) eu sales accelerating (2) world wide base price set after German reimbursement (3) US market start on August 1st. all 3 things are on going in 1 month

0 · Reply

RCBsr4808 Jun. 29 at 1:42 AM

$OTLK it might spike over $2. "To the moon Alice, to the moon."

0 · Reply

Scott2773 Jun. 29 at 1:30 AM

$APLD $APLX $SLS $KEEL $OTLK Love all of these plays(APLD especially…obviously) Feeling

1 · Reply

Applesauce24 Jun. 29 at 1:12 AM

$OTLK Are your brokers still showing that OTLK is out of compliance? I use Robinhood and Fidelity and both are still showing out of compliance, no margin available. Hoping for that to change tomorrow, but not sure how long it usually takes brokers to update after compliance.

3 · Reply